What is claimed is:

1. A recombinant virus comprising a mammalian PTEN-Long gene.

2. The recombinant virus of claim 1, wherein the virus has been modified to target tumor cells.

3. The recombinant virus of claim 1 or 2, wherein the virus has been modified to place genes critical to viral replication under the control of a tumor-specific promoter.

4. The recombinant virus of any one of claims 1 to 3, wherein the recombinant virus comprises a Herpes Simplex Virus- 1 backbone.

5. The recombinant virus of any one of claims 1 to 4, wherein the PTEN-Long gene is operatively linked to a tissue specific promoter.

6. The recombinant virus of any one of claims 1 to 4, wherein the PTEN-Long gene is operatively linked to an inducible promoter.

7. The recombinant virus of any one of claims 1 to 4, wherein the PTEN-Long gene is operatively linked to a constitutive promoter.

8. Use of a recombinant virus of any one of claims 1 to 7 for the manufacture of a medicament for the treatment of a cancer in a subject.

9. Use of a recombinant virus of any one of claims 1 to 7 for the manufacture of a medicament for inhibiting PD-Ll in a cancer cell in a subject.

10. Use of a recombinant virus of any one of claims 1 to 7 for the manufacture of a medicament for increasing the number of infiltrating CD8 T cells at the site of a cancer in a subject.

11. Use of a recombinant virus of any one of claims 1 to 7 for the manufacture of a medicament for increasing the number of infiltrating Natural Killer cells at the site of a cancer in a subject.

12. Use of a recombinant virus of any one of claims 1 to 7 for the manufacture of a medicament for inhibiting the metastasis of a cancer in a subject.

13. Use of a recombinant virus of claim 1 for the manufacture of a medicament for the treatment of a cancer in a subject comprising administering to the subject a recombinant virus comprising a mammalian PTEN-Long gene.

14. The use according to claim 13, wherein the virus has been modified to target tumor cells.

15. The use according to claim 13 or 14, wherein the recombinant virus comprises a Herpes Simplex Virus- 1 backbone.